nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—ABCB1—kidney cancer	0.373	1	CbGaD
Scopolamine—ABCB1—Temsirolimus—kidney cancer	0.0865	0.225	CbGbCtD
Scopolamine—ABCB1—Pazopanib—kidney cancer	0.0455	0.118	CbGbCtD
Scopolamine—ABCB1—Dactinomycin—kidney cancer	0.0416	0.108	CbGbCtD
Scopolamine—ABCB1—Gemcitabine—kidney cancer	0.0329	0.0856	CbGbCtD
Scopolamine—ABCB1—Erlotinib—kidney cancer	0.0324	0.0845	CbGbCtD
Scopolamine—ABCB1—Paclitaxel—kidney cancer	0.0297	0.0773	CbGbCtD
Scopolamine—ABCB1—Sorafenib—kidney cancer	0.0264	0.0687	CbGbCtD
Scopolamine—ABCB1—Vinblastine—kidney cancer	0.026	0.0678	CbGbCtD
Scopolamine—ABCB1—Vincristine—kidney cancer	0.0256	0.0667	CbGbCtD
Scopolamine—ABCB1—Sunitinib—kidney cancer	0.0214	0.0557	CbGbCtD
Scopolamine—ABCB1—Doxorubicin—kidney cancer	0.016	0.0417	CbGbCtD
Scopolamine—CHRM3—ureter—kidney cancer	0.00117	0.764	CbGeAlD
Scopolamine—Conjunctivitis—Paclitaxel—kidney cancer	0.000477	0.00225	CcSEcCtD
Scopolamine—Constipation—Everolimus—kidney cancer	0.000477	0.00225	CcSEcCtD
Scopolamine—Pain—Everolimus—kidney cancer	0.000477	0.00225	CcSEcCtD
Scopolamine—Vomiting—Temsirolimus—kidney cancer	0.000477	0.00225	CcSEcCtD
Scopolamine—Dry mouth—Sunitinib—kidney cancer	0.000475	0.00224	CcSEcCtD
Scopolamine—Nervous system disorder—Sorafenib—kidney cancer	0.000475	0.00224	CcSEcCtD
Scopolamine—Rash—Temsirolimus—kidney cancer	0.000473	0.00223	CcSEcCtD
Scopolamine—Dermatitis—Temsirolimus—kidney cancer	0.000472	0.00223	CcSEcCtD
Scopolamine—Skin disorder—Sorafenib—kidney cancer	0.00047	0.00222	CcSEcCtD
Scopolamine—Arrhythmia—Gemcitabine—kidney cancer	0.00047	0.00222	CcSEcCtD
Scopolamine—Headache—Temsirolimus—kidney cancer	0.00047	0.00222	CcSEcCtD
Scopolamine—Dizziness—Pazopanib—kidney cancer	0.000467	0.0022	CcSEcCtD
Scopolamine—Oedema—Sunitinib—kidney cancer	0.000466	0.0022	CcSEcCtD
Scopolamine—Fatigue—Erlotinib—kidney cancer	0.000464	0.00219	CcSEcCtD
Scopolamine—Feeling abnormal—Vinblastine—kidney cancer	0.000461	0.00218	CcSEcCtD
Scopolamine—Muscular weakness—Capecitabine—kidney cancer	0.000461	0.00217	CcSEcCtD
Scopolamine—Pain—Erlotinib—kidney cancer	0.00046	0.00217	CcSEcCtD
Scopolamine—Constipation—Erlotinib—kidney cancer	0.00046	0.00217	CcSEcCtD
Scopolamine—Feeling abnormal—Everolimus—kidney cancer	0.000459	0.00217	CcSEcCtD
Scopolamine—Erythema—Gemcitabine—kidney cancer	0.000458	0.00216	CcSEcCtD
Scopolamine—Nervous system disorder—Sunitinib—kidney cancer	0.000457	0.00216	CcSEcCtD
Scopolamine—Skin disorder—Sunitinib—kidney cancer	0.000452	0.00213	CcSEcCtD
Scopolamine—Dysphagia—Capecitabine—kidney cancer	0.000451	0.00213	CcSEcCtD
Scopolamine—Vomiting—Pazopanib—kidney cancer	0.000449	0.00212	CcSEcCtD
Scopolamine—Bradycardia—Paclitaxel—kidney cancer	0.000448	0.00212	CcSEcCtD
Scopolamine—Rash—Pazopanib—kidney cancer	0.000445	0.0021	CcSEcCtD
Scopolamine—Nausea—Temsirolimus—kidney cancer	0.000445	0.0021	CcSEcCtD
Scopolamine—Dermatitis—Pazopanib—kidney cancer	0.000445	0.0021	CcSEcCtD
Scopolamine—Agitation—Vincristine—kidney cancer	0.000444	0.00209	CcSEcCtD
Scopolamine—Abdominal pain—Vinblastine—kidney cancer	0.000442	0.00209	CcSEcCtD
Scopolamine—Headache—Pazopanib—kidney cancer	0.000442	0.00209	CcSEcCtD
Scopolamine—Oedema—Dactinomycin—kidney cancer	0.000441	0.00208	CcSEcCtD
Scopolamine—Abdominal pain—Everolimus—kidney cancer	0.000441	0.00208	CcSEcCtD
Scopolamine—Body temperature increased—Everolimus—kidney cancer	0.000441	0.00208	CcSEcCtD
Scopolamine—Pharyngitis—Paclitaxel—kidney cancer	0.000437	0.00206	CcSEcCtD
Scopolamine—Urinary tract disorder—Paclitaxel—kidney cancer	0.000435	0.00205	CcSEcCtD
Scopolamine—Vertigo—Vincristine—kidney cancer	0.000434	0.00205	CcSEcCtD
Scopolamine—Urethral disorder—Paclitaxel—kidney cancer	0.000432	0.00204	CcSEcCtD
Scopolamine—Dry eye—Doxorubicin—kidney cancer	0.000428	0.00202	CcSEcCtD
Scopolamine—Abdominal pain—Erlotinib—kidney cancer	0.000425	0.00201	CcSEcCtD
Scopolamine—Body temperature increased—Erlotinib—kidney cancer	0.000425	0.00201	CcSEcCtD
Scopolamine—Visual impairment—Paclitaxel—kidney cancer	0.000424	0.002	CcSEcCtD
Scopolamine—Dysuria—Capecitabine—kidney cancer	0.000422	0.00199	CcSEcCtD
Scopolamine—Nausea—Pazopanib—kidney cancer	0.000419	0.00198	CcSEcCtD
Scopolamine—Fatigue—Sorafenib—kidney cancer	0.000417	0.00197	CcSEcCtD
Scopolamine—Constipation—Sorafenib—kidney cancer	0.000414	0.00195	CcSEcCtD
Scopolamine—Pain—Sorafenib—kidney cancer	0.000414	0.00195	CcSEcCtD
Scopolamine—Eye disorder—Paclitaxel—kidney cancer	0.000412	0.00194	CcSEcCtD
Scopolamine—Flushing—Paclitaxel—kidney cancer	0.000409	0.00193	CcSEcCtD
Scopolamine—Asthenia—Vinblastine—kidney cancer	0.000402	0.0019	CcSEcCtD
Scopolamine—Fatigue—Sunitinib—kidney cancer	0.000402	0.00189	CcSEcCtD
Scopolamine—Asthenia—Everolimus—kidney cancer	0.0004	0.00189	CcSEcCtD
Scopolamine—Constipation—Sunitinib—kidney cancer	0.000398	0.00188	CcSEcCtD
Scopolamine—Pain—Sunitinib—kidney cancer	0.000398	0.00188	CcSEcCtD
Scopolamine—Pruritus—Everolimus—kidney cancer	0.000394	0.00186	CcSEcCtD
Scopolamine—Oedema—Vincristine—kidney cancer	0.000394	0.00186	CcSEcCtD
Scopolamine—Arrhythmia—Paclitaxel—kidney cancer	0.000393	0.00186	CcSEcCtD
Scopolamine—Conjunctivitis—Capecitabine—kidney cancer	0.000391	0.00185	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000387	0.00183	CcSEcCtD
Scopolamine—Nervous system disorder—Vincristine—kidney cancer	0.000386	0.00182	CcSEcCtD
Scopolamine—Asthenia—Erlotinib—kidney cancer	0.000386	0.00182	CcSEcCtD
Scopolamine—Mental disorder—Paclitaxel—kidney cancer	0.000386	0.00182	CcSEcCtD
Scopolamine—Erythema—Paclitaxel—kidney cancer	0.000383	0.00181	CcSEcCtD
Scopolamine—Body temperature increased—Sorafenib—kidney cancer	0.000383	0.00181	CcSEcCtD
Scopolamine—Abdominal pain—Sorafenib—kidney cancer	0.000383	0.00181	CcSEcCtD
Scopolamine—Hyperhidrosis—Vincristine—kidney cancer	0.000381	0.0018	CcSEcCtD
Scopolamine—Pruritus—Erlotinib—kidney cancer	0.000381	0.0018	CcSEcCtD
Scopolamine—Fatigue—Dactinomycin—kidney cancer	0.00038	0.00179	CcSEcCtD
Scopolamine—Pain—Dactinomycin—kidney cancer	0.000377	0.00178	CcSEcCtD
Scopolamine—Eczema—Doxorubicin—kidney cancer	0.000375	0.00177	CcSEcCtD
Scopolamine—Oedema—Gemcitabine—kidney cancer	0.000374	0.00176	CcSEcCtD
Scopolamine—Dizziness—Vinblastine—kidney cancer	0.00037	0.00175	CcSEcCtD
Scopolamine—Dizziness—Everolimus—kidney cancer	0.000369	0.00174	CcSEcCtD
Scopolamine—Abdominal pain—Sunitinib—kidney cancer	0.000368	0.00174	CcSEcCtD
Scopolamine—Body temperature increased—Sunitinib—kidney cancer	0.000368	0.00174	CcSEcCtD
Scopolamine—Hypotension—Vincristine—kidney cancer	0.000368	0.00174	CcSEcCtD
Scopolamine—Bradycardia—Capecitabine—kidney cancer	0.000368	0.00174	CcSEcCtD
Scopolamine—Nervous system disorder—Gemcitabine—kidney cancer	0.000366	0.00173	CcSEcCtD
Scopolamine—Feeling abnormal—Dactinomycin—kidney cancer	0.000363	0.00171	CcSEcCtD
Scopolamine—Skin disorder—Gemcitabine—kidney cancer	0.000363	0.00171	CcSEcCtD
Scopolamine—Vision blurred—Paclitaxel—kidney cancer	0.000361	0.00171	CcSEcCtD
Scopolamine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000361	0.0017	CcSEcCtD
Scopolamine—Tremor—Paclitaxel—kidney cancer	0.000359	0.0017	CcSEcCtD
Scopolamine—Pharyngitis—Capecitabine—kidney cancer	0.000359	0.00169	CcSEcCtD
Scopolamine—Urinary tract disorder—Capecitabine—kidney cancer	0.000357	0.00168	CcSEcCtD
Scopolamine—Vomiting—Vinblastine—kidney cancer	0.000356	0.00168	CcSEcCtD
Scopolamine—Dizziness—Erlotinib—kidney cancer	0.000356	0.00168	CcSEcCtD
Scopolamine—Vomiting—Everolimus—kidney cancer	0.000355	0.00167	CcSEcCtD
Scopolamine—Urethral disorder—Capecitabine—kidney cancer	0.000354	0.00167	CcSEcCtD
Scopolamine—Agitation—Paclitaxel—kidney cancer	0.000352	0.00166	CcSEcCtD
Scopolamine—Rash—Everolimus—kidney cancer	0.000352	0.00166	CcSEcCtD
Scopolamine—Dermatitis—Everolimus—kidney cancer	0.000351	0.00166	CcSEcCtD
Scopolamine—Headache—Vinblastine—kidney cancer	0.000351	0.00165	CcSEcCtD
Scopolamine—Headache—Everolimus—kidney cancer	0.000349	0.00165	CcSEcCtD
Scopolamine—Hypotension—Gemcitabine—kidney cancer	0.000349	0.00165	CcSEcCtD
Scopolamine—Body temperature increased—Dactinomycin—kidney cancer	0.000349	0.00164	CcSEcCtD
Scopolamine—Abdominal pain—Dactinomycin—kidney cancer	0.000349	0.00164	CcSEcCtD
Scopolamine—Visual impairment—Capecitabine—kidney cancer	0.000348	0.00164	CcSEcCtD
Scopolamine—Asthenia—Sorafenib—kidney cancer	0.000347	0.00164	CcSEcCtD
Scopolamine—Vertigo—Paclitaxel—kidney cancer	0.000344	0.00163	CcSEcCtD
Scopolamine—Pruritus—Sorafenib—kidney cancer	0.000342	0.00162	CcSEcCtD
Scopolamine—Vomiting—Erlotinib—kidney cancer	0.000342	0.00161	CcSEcCtD
Scopolamine—Fatigue—Vincristine—kidney cancer	0.00034	0.0016	CcSEcCtD
Scopolamine—Rash—Erlotinib—kidney cancer	0.000339	0.0016	CcSEcCtD
Scopolamine—Dermatitis—Erlotinib—kidney cancer	0.000339	0.0016	CcSEcCtD
Scopolamine—Eye disorder—Capecitabine—kidney cancer	0.000338	0.00159	CcSEcCtD
Scopolamine—Headache—Erlotinib—kidney cancer	0.000337	0.00159	CcSEcCtD
Scopolamine—Pain—Vincristine—kidney cancer	0.000337	0.00159	CcSEcCtD
Scopolamine—Constipation—Vincristine—kidney cancer	0.000337	0.00159	CcSEcCtD
Scopolamine—Flushing—Capecitabine—kidney cancer	0.000335	0.00158	CcSEcCtD
Scopolamine—Asthenia—Sunitinib—kidney cancer	0.000334	0.00158	CcSEcCtD
Scopolamine—Nausea—Vinblastine—kidney cancer	0.000332	0.00157	CcSEcCtD
Scopolamine—Somnolence—Gemcitabine—kidney cancer	0.000332	0.00157	CcSEcCtD
Scopolamine—Nausea—Everolimus—kidney cancer	0.000331	0.00156	CcSEcCtD
Scopolamine—Pruritus—Sunitinib—kidney cancer	0.000329	0.00155	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000324	0.00153	CcSEcCtD
Scopolamine—Arrhythmia—Capecitabine—kidney cancer	0.000323	0.00152	CcSEcCtD
Scopolamine—Fatigue—Gemcitabine—kidney cancer	0.000322	0.00152	CcSEcCtD
Scopolamine—Dizziness—Sorafenib—kidney cancer	0.00032	0.00151	CcSEcCtD
Scopolamine—Constipation—Gemcitabine—kidney cancer	0.00032	0.00151	CcSEcCtD
Scopolamine—Pain—Gemcitabine—kidney cancer	0.00032	0.00151	CcSEcCtD
Scopolamine—Nausea—Erlotinib—kidney cancer	0.00032	0.00151	CcSEcCtD
Scopolamine—Dry mouth—Paclitaxel—kidney cancer	0.000319	0.00151	CcSEcCtD
Scopolamine—Mental disorder—Capecitabine—kidney cancer	0.000317	0.00149	CcSEcCtD
Scopolamine—Asthenia—Dactinomycin—kidney cancer	0.000316	0.00149	CcSEcCtD
Scopolamine—Confusional state—Paclitaxel—kidney cancer	0.000315	0.00149	CcSEcCtD
Scopolamine—Erythema—Capecitabine—kidney cancer	0.000315	0.00148	CcSEcCtD
Scopolamine—Oedema—Paclitaxel—kidney cancer	0.000313	0.00148	CcSEcCtD
Scopolamine—Abdominal pain—Vincristine—kidney cancer	0.000311	0.00147	CcSEcCtD
Scopolamine—Body temperature increased—Vincristine—kidney cancer	0.000311	0.00147	CcSEcCtD
Scopolamine—Dry skin—Doxorubicin—kidney cancer	0.000309	0.00146	CcSEcCtD
Scopolamine—Dizziness—Sunitinib—kidney cancer	0.000308	0.00145	CcSEcCtD
Scopolamine—Feeling abnormal—Gemcitabine—kidney cancer	0.000308	0.00145	CcSEcCtD
Scopolamine—Vomiting—Sorafenib—kidney cancer	0.000308	0.00145	CcSEcCtD
Scopolamine—Nervous system disorder—Paclitaxel—kidney cancer	0.000307	0.00145	CcSEcCtD
Scopolamine—Tachycardia—Paclitaxel—kidney cancer	0.000305	0.00144	CcSEcCtD
Scopolamine—Rash—Sorafenib—kidney cancer	0.000305	0.00144	CcSEcCtD
Scopolamine—Dermatitis—Sorafenib—kidney cancer	0.000305	0.00144	CcSEcCtD
Scopolamine—Skin disorder—Paclitaxel—kidney cancer	0.000304	0.00143	CcSEcCtD
Scopolamine—Headache—Sorafenib—kidney cancer	0.000303	0.00143	CcSEcCtD
Scopolamine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000302	0.00143	CcSEcCtD
Scopolamine—Muscular weakness—Doxorubicin—kidney cancer	0.000297	0.0014	CcSEcCtD
Scopolamine—Vision blurred—Capecitabine—kidney cancer	0.000296	0.0014	CcSEcCtD
Scopolamine—Vomiting—Sunitinib—kidney cancer	0.000296	0.0014	CcSEcCtD
Scopolamine—Body temperature increased—Gemcitabine—kidney cancer	0.000295	0.00139	CcSEcCtD
Scopolamine—Tremor—Capecitabine—kidney cancer	0.000295	0.00139	CcSEcCtD
Scopolamine—Rash—Sunitinib—kidney cancer	0.000294	0.00139	CcSEcCtD
Scopolamine—Dermatitis—Sunitinib—kidney cancer	0.000293	0.00138	CcSEcCtD
Scopolamine—Hypotension—Paclitaxel—kidney cancer	0.000292	0.00138	CcSEcCtD
Scopolamine—Headache—Sunitinib—kidney cancer	0.000292	0.00138	CcSEcCtD
Scopolamine—Dysphagia—Doxorubicin—kidney cancer	0.000291	0.00137	CcSEcCtD
Scopolamine—Nausea—Sorafenib—kidney cancer	0.000287	0.00136	CcSEcCtD
Scopolamine—Vertigo—Capecitabine—kidney cancer	0.000283	0.00133	CcSEcCtD
Scopolamine—Asthenia—Vincristine—kidney cancer	0.000283	0.00133	CcSEcCtD
Scopolamine—Vomiting—Dactinomycin—kidney cancer	0.00028	0.00132	CcSEcCtD
Scopolamine—Somnolence—Paclitaxel—kidney cancer	0.000278	0.00131	CcSEcCtD
Scopolamine—Rash—Dactinomycin—kidney cancer	0.000278	0.00131	CcSEcCtD
Scopolamine—Nausea—Sunitinib—kidney cancer	0.000277	0.00131	CcSEcCtD
Scopolamine—Dysuria—Doxorubicin—kidney cancer	0.000272	0.00128	CcSEcCtD
Scopolamine—Fatigue—Paclitaxel—kidney cancer	0.00027	0.00127	CcSEcCtD
Scopolamine—Asthenia—Gemcitabine—kidney cancer	0.000268	0.00127	CcSEcCtD
Scopolamine—Constipation—Paclitaxel—kidney cancer	0.000268	0.00126	CcSEcCtD
Scopolamine—Pain—Paclitaxel—kidney cancer	0.000268	0.00126	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000266	0.00126	CcSEcCtD
Scopolamine—Pruritus—Gemcitabine—kidney cancer	0.000264	0.00125	CcSEcCtD
Scopolamine—Dry mouth—Capecitabine—kidney cancer	0.000262	0.00124	CcSEcCtD
Scopolamine—Nausea—Dactinomycin—kidney cancer	0.000262	0.00124	CcSEcCtD
Scopolamine—Dizziness—Vincristine—kidney cancer	0.00026	0.00123	CcSEcCtD
Scopolamine—Drowsiness—Doxorubicin—kidney cancer	0.000259	0.00122	CcSEcCtD
Scopolamine—Confusional state—Capecitabine—kidney cancer	0.000259	0.00122	CcSEcCtD
Scopolamine—Feeling abnormal—Paclitaxel—kidney cancer	0.000258	0.00122	CcSEcCtD
Scopolamine—Oedema—Capecitabine—kidney cancer	0.000257	0.00121	CcSEcCtD
Scopolamine—Conjunctivitis—Doxorubicin—kidney cancer	0.000252	0.00119	CcSEcCtD
Scopolamine—Nervous system disorder—Capecitabine—kidney cancer	0.000252	0.00119	CcSEcCtD
Scopolamine—Tachycardia—Capecitabine—kidney cancer	0.000251	0.00118	CcSEcCtD
Scopolamine—Vomiting—Vincristine—kidney cancer	0.00025	0.00118	CcSEcCtD
Scopolamine—Skin disorder—Capecitabine—kidney cancer	0.000249	0.00118	CcSEcCtD
Scopolamine—Sweating—Doxorubicin—kidney cancer	0.000249	0.00117	CcSEcCtD
Scopolamine—Rash—Vincristine—kidney cancer	0.000248	0.00117	CcSEcCtD
Scopolamine—Hyperhidrosis—Capecitabine—kidney cancer	0.000248	0.00117	CcSEcCtD
Scopolamine—Dermatitis—Vincristine—kidney cancer	0.000248	0.00117	CcSEcCtD
Scopolamine—Abdominal pain—Paclitaxel—kidney cancer	0.000247	0.00117	CcSEcCtD
Scopolamine—Body temperature increased—Paclitaxel—kidney cancer	0.000247	0.00117	CcSEcCtD
Scopolamine—Headache—Vincristine—kidney cancer	0.000247	0.00116	CcSEcCtD
Scopolamine—Hypotension—Capecitabine—kidney cancer	0.00024	0.00113	CcSEcCtD
Scopolamine—Vomiting—Gemcitabine—kidney cancer	0.000238	0.00112	CcSEcCtD
Scopolamine—Bradycardia—Doxorubicin—kidney cancer	0.000237	0.00112	CcSEcCtD
Scopolamine—Rash—Gemcitabine—kidney cancer	0.000236	0.00111	CcSEcCtD
Scopolamine—Dermatitis—Gemcitabine—kidney cancer	0.000235	0.00111	CcSEcCtD
Scopolamine—Headache—Gemcitabine—kidney cancer	0.000234	0.0011	CcSEcCtD
Scopolamine—Nausea—Vincristine—kidney cancer	0.000234	0.0011	CcSEcCtD
Scopolamine—Pharyngitis—Doxorubicin—kidney cancer	0.000231	0.00109	CcSEcCtD
Scopolamine—Urinary tract disorder—Doxorubicin—kidney cancer	0.00023	0.00109	CcSEcCtD
Scopolamine—Urethral disorder—Doxorubicin—kidney cancer	0.000228	0.00108	CcSEcCtD
Scopolamine—Visual impairment—Doxorubicin—kidney cancer	0.000224	0.00106	CcSEcCtD
Scopolamine—Asthenia—Paclitaxel—kidney cancer	0.000224	0.00106	CcSEcCtD
Scopolamine—Nausea—Gemcitabine—kidney cancer	0.000222	0.00105	CcSEcCtD
Scopolamine—Fatigue—Capecitabine—kidney cancer	0.000221	0.00104	CcSEcCtD
Scopolamine—Pruritus—Paclitaxel—kidney cancer	0.000221	0.00104	CcSEcCtD
Scopolamine—Pain—Capecitabine—kidney cancer	0.00022	0.00104	CcSEcCtD
Scopolamine—Constipation—Capecitabine—kidney cancer	0.00022	0.00104	CcSEcCtD
Scopolamine—Eye disorder—Doxorubicin—kidney cancer	0.000218	0.00103	CcSEcCtD
Scopolamine—Flushing—Doxorubicin—kidney cancer	0.000216	0.00102	CcSEcCtD
Scopolamine—Feeling abnormal—Capecitabine—kidney cancer	0.000212	0.000999	CcSEcCtD
Scopolamine—Arrhythmia—Doxorubicin—kidney cancer	0.000208	0.000982	CcSEcCtD
Scopolamine—Dizziness—Paclitaxel—kidney cancer	0.000207	0.000976	CcSEcCtD
Scopolamine—Mental disorder—Doxorubicin—kidney cancer	0.000204	0.000963	CcSEcCtD
Scopolamine—Abdominal pain—Capecitabine—kidney cancer	0.000203	0.000958	CcSEcCtD
Scopolamine—Body temperature increased—Capecitabine—kidney cancer	0.000203	0.000958	CcSEcCtD
Scopolamine—Erythema—Doxorubicin—kidney cancer	0.000203	0.000957	CcSEcCtD
Scopolamine—Vomiting—Paclitaxel—kidney cancer	0.000199	0.000939	CcSEcCtD
Scopolamine—Rash—Paclitaxel—kidney cancer	0.000197	0.000931	CcSEcCtD
Scopolamine—Dermatitis—Paclitaxel—kidney cancer	0.000197	0.00093	CcSEcCtD
Scopolamine—Headache—Paclitaxel—kidney cancer	0.000196	0.000925	CcSEcCtD
Scopolamine—Vision blurred—Doxorubicin—kidney cancer	0.000191	0.000902	CcSEcCtD
Scopolamine—Agitation—Doxorubicin—kidney cancer	0.000186	0.000879	CcSEcCtD
Scopolamine—Nausea—Paclitaxel—kidney cancer	0.000186	0.000877	CcSEcCtD
Scopolamine—Asthenia—Capecitabine—kidney cancer	0.000184	0.000869	CcSEcCtD
Scopolamine—Vertigo—Doxorubicin—kidney cancer	0.000182	0.00086	CcSEcCtD
Scopolamine—Pruritus—Capecitabine—kidney cancer	0.000182	0.000857	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000171	0.000809	CcSEcCtD
Scopolamine—Dizziness—Capecitabine—kidney cancer	0.00017	0.000801	CcSEcCtD
Scopolamine—Dry mouth—Doxorubicin—kidney cancer	0.000169	0.000797	CcSEcCtD
Scopolamine—Confusional state—Doxorubicin—kidney cancer	0.000167	0.000788	CcSEcCtD
Scopolamine—Oedema—Doxorubicin—kidney cancer	0.000166	0.000781	CcSEcCtD
Scopolamine—Vomiting—Capecitabine—kidney cancer	0.000163	0.00077	CcSEcCtD
Scopolamine—Nervous system disorder—Doxorubicin—kidney cancer	0.000162	0.000766	CcSEcCtD
Scopolamine—Rash—Capecitabine—kidney cancer	0.000162	0.000764	CcSEcCtD
Scopolamine—Dermatitis—Capecitabine—kidney cancer	0.000162	0.000763	CcSEcCtD
Scopolamine—Tachycardia—Doxorubicin—kidney cancer	0.000162	0.000762	CcSEcCtD
Scopolamine—Headache—Capecitabine—kidney cancer	0.000161	0.000759	CcSEcCtD
Scopolamine—Skin disorder—Doxorubicin—kidney cancer	0.000161	0.000759	CcSEcCtD
Scopolamine—Hyperhidrosis—Doxorubicin—kidney cancer	0.00016	0.000755	CcSEcCtD
Scopolamine—Hypotension—Doxorubicin—kidney cancer	0.000155	0.00073	CcSEcCtD
Scopolamine—Nausea—Capecitabine—kidney cancer	0.000153	0.00072	CcSEcCtD
Scopolamine—Somnolence—Doxorubicin—kidney cancer	0.000147	0.000694	CcSEcCtD
Scopolamine—Fatigue—Doxorubicin—kidney cancer	0.000143	0.000673	CcSEcCtD
Scopolamine—Pain—Doxorubicin—kidney cancer	0.000142	0.000668	CcSEcCtD
Scopolamine—Constipation—Doxorubicin—kidney cancer	0.000142	0.000668	CcSEcCtD
Scopolamine—Feeling abnormal—Doxorubicin—kidney cancer	0.000136	0.000644	CcSEcCtD
Scopolamine—Body temperature increased—Doxorubicin—kidney cancer	0.000131	0.000617	CcSEcCtD
Scopolamine—Abdominal pain—Doxorubicin—kidney cancer	0.000131	0.000617	CcSEcCtD
Scopolamine—Asthenia—Doxorubicin—kidney cancer	0.000119	0.00056	CcSEcCtD
Scopolamine—Pruritus—Doxorubicin—kidney cancer	0.000117	0.000553	CcSEcCtD
Scopolamine—Dizziness—Doxorubicin—kidney cancer	0.000109	0.000517	CcSEcCtD
Scopolamine—Vomiting—Doxorubicin—kidney cancer	0.000105	0.000497	CcSEcCtD
Scopolamine—Rash—Doxorubicin—kidney cancer	0.000104	0.000492	CcSEcCtD
Scopolamine—Dermatitis—Doxorubicin—kidney cancer	0.000104	0.000492	CcSEcCtD
Scopolamine—Headache—Doxorubicin—kidney cancer	0.000104	0.000489	CcSEcCtD
Scopolamine—Nausea—Doxorubicin—kidney cancer	9.83e-05	0.000464	CcSEcCtD
Scopolamine—CHRM3—renal system—kidney cancer	9.33e-05	0.0608	CbGeAlD
Scopolamine—CHRM3—kidney—kidney cancer	9.02e-05	0.0587	CbGeAlD
Scopolamine—ABCB1—nephron tubule—kidney cancer	3.99e-05	0.026	CbGeAlD
Scopolamine—ABCB1—renal system—kidney cancer	3.63e-05	0.0236	CbGeAlD
Scopolamine—ABCB1—kidney—kidney cancer	3.51e-05	0.0229	CbGeAlD
Scopolamine—ABCB1—cortex of kidney—kidney cancer	3.42e-05	0.0223	CbGeAlD
Scopolamine—ABCB1—gonad—kidney cancer	3.25e-05	0.0212	CbGeAlD
Scopolamine—CHRM3—Metabolism—PTGS1—kidney cancer	1.45e-05	0.000498	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ITPR2—kidney cancer	1.42e-05	0.000489	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PSMD7—kidney cancer	1.42e-05	0.000488	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ITPR2—kidney cancer	1.42e-05	0.000487	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.41e-05	0.000485	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ITPR2—kidney cancer	1.4e-05	0.000483	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—POMC—kidney cancer	1.4e-05	0.000483	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.37e-05	0.000472	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CA9—kidney cancer	1.36e-05	0.000468	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—BCHE—kidney cancer	1.35e-05	0.000463	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.34e-05	0.000462	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—SLC5A5—kidney cancer	1.33e-05	0.000457	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IGF2—kidney cancer	1.3e-05	0.000446	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CDKN2B—kidney cancer	1.29e-05	0.000444	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CTNNA1—kidney cancer	1.29e-05	0.000443	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CTNNA1—kidney cancer	1.28e-05	0.000442	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—SLC2A1—kidney cancer	1.28e-05	0.000442	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EIF4EBP1—kidney cancer	1.28e-05	0.000441	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HSPB1—kidney cancer	1.28e-05	0.000441	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EIF4EBP1—kidney cancer	1.28e-05	0.000439	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HSPB1—kidney cancer	1.28e-05	0.000439	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CTNNA1—kidney cancer	1.27e-05	0.000438	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.27e-05	0.000436	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EIF4EBP1—kidney cancer	1.26e-05	0.000435	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HSPB1—kidney cancer	1.26e-05	0.000435	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IGF1R—kidney cancer	1.25e-05	0.000431	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IGF2—kidney cancer	1.24e-05	0.000427	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CDKN2B—kidney cancer	1.24e-05	0.000425	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—RAF1—kidney cancer	1.21e-05	0.000416	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IGF1R—kidney cancer	1.2e-05	0.000413	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—IL2—kidney cancer	1.19e-05	0.00041	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PSMD7—kidney cancer	1.19e-05	0.00041	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TSC1—kidney cancer	1.19e-05	0.00041	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ANXA1—kidney cancer	1.19e-05	0.00041	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TSC1—kidney cancer	1.19e-05	0.000408	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ANXA1—kidney cancer	1.19e-05	0.000408	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PSMD7—kidney cancer	1.19e-05	0.000408	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PSMD7—kidney cancer	1.18e-05	0.000404	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TSC1—kidney cancer	1.18e-05	0.000404	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ANXA1—kidney cancer	1.18e-05	0.000404	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.16e-05	0.000401	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—RAF1—kidney cancer	1.16e-05	0.000398	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CRABP1—kidney cancer	1.16e-05	0.000398	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—FLT1—kidney cancer	1.15e-05	0.000397	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—FLT1—kidney cancer	1.15e-05	0.000396	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—IL2—kidney cancer	1.14e-05	0.000393	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—FLT1—kidney cancer	1.14e-05	0.000392	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.13e-05	0.000388	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—POMC—kidney cancer	1.09e-05	0.000374	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—POMC—kidney cancer	1.08e-05	0.000373	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL2—kidney cancer	1.08e-05	0.000373	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ITPR2—kidney cancer	1.07e-05	0.00037	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—POMC—kidney cancer	1.07e-05	0.000369	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—GSTP1—kidney cancer	1.07e-05	0.000368	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—JUNB—kidney cancer	1.07e-05	0.000368	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PAK1—kidney cancer	1.07e-05	0.000368	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PAK1—kidney cancer	1.07e-05	0.000367	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—JUNB—kidney cancer	1.07e-05	0.000367	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PAK1—kidney cancer	1.05e-05	0.000363	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—JUNB—kidney cancer	1.05e-05	0.000363	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL2—kidney cancer	1.04e-05	0.000357	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—HIF1A—kidney cancer	1.03e-05	0.000355	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TSC2—kidney cancer	1.03e-05	0.000354	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—ABCB1—kidney cancer	1.01e-05	0.000349	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—HIF1A—kidney cancer	9.88e-06	0.00034	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—POMC—kidney cancer	9.87e-06	0.00034	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—KDR—kidney cancer	9.86e-06	0.00034	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TSC2—kidney cancer	9.85e-06	0.000339	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—POMC—kidney cancer	9.84e-06	0.000339	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—GSTM1—kidney cancer	9.84e-06	0.000339	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTT1—kidney cancer	9.8e-06	0.000337	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ACHE—kidney cancer	9.8e-06	0.000337	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—POMC—kidney cancer	9.74e-06	0.000335	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—KDR—kidney cancer	9.45e-06	0.000325	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—CYP1A1—kidney cancer	9.32e-06	0.000321	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—SCARB1—kidney cancer	9.27e-06	0.000319	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTGS1—kidney cancer	9.18e-06	0.000316	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—KIT—kidney cancer	9.09e-06	0.000313	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—APC—kidney cancer	9.09e-06	0.000313	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PSMD7—kidney cancer	9e-06	0.00031	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IGF2—kidney cancer	8.74e-06	0.000301	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IGF2—kidney cancer	8.71e-06	0.0003	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—MAPK3—kidney cancer	8.7e-06	0.0003	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—KIT—kidney cancer	8.7e-06	0.000299	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—APC—kidney cancer	8.7e-06	0.000299	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN2B—kidney cancer	8.7e-06	0.000299	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN2B—kidney cancer	8.67e-06	0.000298	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—POMC—kidney cancer	8.65e-06	0.000298	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IGF2—kidney cancer	8.62e-06	0.000297	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN2B—kidney cancer	8.59e-06	0.000296	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—BRAF—kidney cancer	8.54e-06	0.000294	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—BCHE—kidney cancer	8.54e-06	0.000294	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IGF1R—kidney cancer	8.45e-06	0.000291	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—SLC5A5—kidney cancer	8.43e-06	0.00029	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IGF1R—kidney cancer	8.42e-06	0.00029	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IGF1R—kidney cancer	8.34e-06	0.000287	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—MAPK3—kidney cancer	8.33e-06	0.000287	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—POMC—kidney cancer	8.28e-06	0.000285	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—MAPK1—kidney cancer	8.28e-06	0.000285	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—BRAF—kidney cancer	8.18e-06	0.000282	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—SLC2A1—kidney cancer	8.14e-06	0.00028	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—RAF1—kidney cancer	8.14e-06	0.00028	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—RAF1—kidney cancer	8.11e-06	0.000279	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—IL2—kidney cancer	8.04e-06	0.000277	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—RAF1—kidney cancer	8.03e-06	0.000277	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—IL2—kidney cancer	8.01e-06	0.000276	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—IL2—kidney cancer	7.93e-06	0.000273	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—MAPK1—kidney cancer	7.93e-06	0.000273	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—PIK3CA—kidney cancer	7.91e-06	0.000272	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—KRAS—kidney cancer	7.82e-06	0.000269	CbGpPWpGaD
Scopolamine—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	7.77e-06	0.000267	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—PIK3CA—kidney cancer	7.58e-06	0.000261	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—KRAS—kidney cancer	7.49e-06	0.000258	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL2—kidney cancer	7.3e-06	0.000251	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL2—kidney cancer	7.27e-06	0.00025	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL2—kidney cancer	7.2e-06	0.000248	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—PIK3CA—kidney cancer	7.18e-06	0.000247	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—RAF1—kidney cancer	7.13e-06	0.000245	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—RELA—kidney cancer	7.1e-06	0.000244	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—ERBB2—kidney cancer	7.05e-06	0.000243	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MTOR—kidney cancer	6.96e-06	0.00024	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HIF1A—kidney cancer	6.95e-06	0.000239	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—POMC—kidney cancer	6.95e-06	0.000239	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TSC2—kidney cancer	6.94e-06	0.000239	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HIF1A—kidney cancer	6.93e-06	0.000239	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TSC2—kidney cancer	6.91e-06	0.000238	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—PIK3CA—kidney cancer	6.88e-06	0.000237	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HIF1A—kidney cancer	6.86e-06	0.000236	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TSC2—kidney cancer	6.85e-06	0.000236	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—RAF1—kidney cancer	6.83e-06	0.000235	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—RELA—kidney cancer	6.8e-06	0.000234	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTP1—kidney cancer	6.79e-06	0.000234	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—ERBB2—kidney cancer	6.76e-06	0.000233	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MTOR—kidney cancer	6.67e-06	0.000229	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KDR—kidney cancer	6.65e-06	0.000229	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KDR—kidney cancer	6.63e-06	0.000228	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KDR—kidney cancer	6.56e-06	0.000226	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CDKN1B—kidney cancer	6.53e-06	0.000225	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL2—kidney cancer	6.39e-06	0.00022	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CDKN1B—kidney cancer	6.26e-06	0.000215	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTM1—kidney cancer	6.24e-06	0.000215	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCND1—kidney cancer	6.23e-06	0.000215	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—JUN—kidney cancer	6.22e-06	0.000214	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CTNNB1—kidney cancer	6.17e-06	0.000212	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KIT—kidney cancer	6.13e-06	0.000211	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—APC—kidney cancer	6.13e-06	0.000211	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL2—kidney cancer	6.12e-06	0.000211	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KIT—kidney cancer	6.11e-06	0.00021	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—APC—kidney cancer	6.11e-06	0.00021	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—APC—kidney cancer	6.05e-06	0.000208	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KIT—kidney cancer	6.05e-06	0.000208	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PTEN—kidney cancer	6.02e-06	0.000207	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCND1—kidney cancer	5.97e-06	0.000205	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—JUN—kidney cancer	5.96e-06	0.000205	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CYP1A1—kidney cancer	5.92e-06	0.000204	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CTNNB1—kidney cancer	5.91e-06	0.000203	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	5.87e-06	0.000202	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—MAPK3—kidney cancer	5.85e-06	0.000201	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—POMC—kidney cancer	5.83e-06	0.000201	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—POMC—kidney cancer	5.81e-06	0.0002	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—MAPK3—kidney cancer	5.79e-06	0.000199	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PTEN—kidney cancer	5.76e-06	0.000198	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—BRAF—kidney cancer	5.76e-06	0.000198	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—POMC—kidney cancer	5.76e-06	0.000198	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—BRAF—kidney cancer	5.74e-06	0.000198	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—BRAF—kidney cancer	5.68e-06	0.000196	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	5.58e-06	0.000192	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—MAPK1—kidney cancer	5.56e-06	0.000192	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTGS2—kidney cancer	5.55e-06	0.000191	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—MAPK1—kidney cancer	5.51e-06	0.00019	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—VEGFA—kidney cancer	5.43e-06	0.000187	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	5.33e-06	0.000184	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—PIK3CA—kidney cancer	5.32e-06	0.000183	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—KRAS—kidney cancer	5.27e-06	0.000181	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—PIK3CA—kidney cancer	5.27e-06	0.000181	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—KRAS—kidney cancer	5.26e-06	0.000181	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—KRAS—kidney cancer	5.2e-06	0.000179	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—VEGFA—kidney cancer	5.2e-06	0.000179	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MAPK3—kidney cancer	5.14e-06	0.000177	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MYC—kidney cancer	5e-06	0.000172	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MAPK3—kidney cancer	4.92e-06	0.000169	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MAPK1—kidney cancer	4.89e-06	0.000168	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	4.84e-06	0.000167	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTEN—kidney cancer	4.84e-06	0.000166	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	4.83e-06	0.000166	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—RAF1—kidney cancer	4.81e-06	0.000166	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—RAF1—kidney cancer	4.79e-06	0.000165	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MYC—kidney cancer	4.79e-06	0.000165	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—RELA—kidney cancer	4.79e-06	0.000165	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	4.78e-06	0.000165	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—RELA—kidney cancer	4.77e-06	0.000164	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ERBB2—kidney cancer	4.76e-06	0.000164	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—RAF1—kidney cancer	4.75e-06	0.000163	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ERBB2—kidney cancer	4.74e-06	0.000163	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—RELA—kidney cancer	4.73e-06	0.000163	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ERBB2—kidney cancer	4.7e-06	0.000162	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MTOR—kidney cancer	4.69e-06	0.000162	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MAPK1—kidney cancer	4.68e-06	0.000161	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MTOR—kidney cancer	4.68e-06	0.000161	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MTOR—kidney cancer	4.63e-06	0.00016	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—KRAS—kidney cancer	4.62e-06	0.000159	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—KRAS—kidney cancer	4.42e-06	0.000152	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—POMC—kidney cancer	4.41e-06	0.000152	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	4.41e-06	0.000152	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	4.39e-06	0.000151	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	4.35e-06	0.00015	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL2—kidney cancer	4.31e-06	0.000148	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL2—kidney cancer	4.3e-06	0.000148	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL2—kidney cancer	4.26e-06	0.000146	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3CA—kidney cancer	4.24e-06	0.000146	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCND1—kidney cancer	4.2e-06	0.000145	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—JUN—kidney cancer	4.19e-06	0.000144	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCND1—kidney cancer	4.19e-06	0.000144	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—JUN—kidney cancer	4.18e-06	0.000144	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	4.16e-06	0.000143	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCND1—kidney cancer	4.15e-06	0.000143	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	4.15e-06	0.000143	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—JUN—kidney cancer	4.14e-06	0.000143	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	4.11e-06	0.000141	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TP53—kidney cancer	4.11e-06	0.000141	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3CA—kidney cancer	4.06e-06	0.00014	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PTEN—kidney cancer	4.06e-06	0.00014	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PTEN—kidney cancer	4.04e-06	0.000139	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PTEN—kidney cancer	4e-06	0.000138	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TP53—kidney cancer	3.93e-06	0.000135	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—VEGFA—kidney cancer	3.66e-06	0.000126	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—VEGFA—kidney cancer	3.65e-06	0.000126	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—VEGFA—kidney cancer	3.62e-06	0.000124	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTGS2—kidney cancer	3.52e-06	0.000121	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAPK3—kidney cancer	3.47e-06	0.000119	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAPK3—kidney cancer	3.45e-06	0.000119	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAPK3—kidney cancer	3.42e-06	0.000118	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CA—kidney cancer	3.41e-06	0.000117	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MYC—kidney cancer	3.37e-06	0.000116	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MYC—kidney cancer	3.36e-06	0.000116	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MYC—kidney cancer	3.33e-06	0.000115	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAPK1—kidney cancer	3.3e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAPK1—kidney cancer	3.29e-06	0.000113	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAPK1—kidney cancer	3.26e-06	0.000112	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KRAS—kidney cancer	3.11e-06	0.000107	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KRAS—kidney cancer	3.1e-06	0.000107	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KRAS—kidney cancer	3.07e-06	0.000106	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTEN—kidney cancer	3.07e-06	0.000106	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.86e-06	9.85e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	2.85e-06	9.82e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	2.82e-06	9.72e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TP53—kidney cancer	2.77e-06	9.53e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TP53—kidney cancer	2.76e-06	9.5e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TP53—kidney cancer	2.73e-06	9.41e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CA—kidney cancer	2.16e-06	7.45e-05	CbGpPWpGaD
